AbCellera Biologics Inc. (ABCL)
Summary
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 14,495 | $72,909.44 | $151,400.27 | $78,490.83 | 107.66% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 98 | $342.02 | $1,024.59 | $682.57 | 199.57% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1.23M | $9.68M | $8.57M | -$1.11M | -11.51% |
 John H. Burbank III Passport Capital LLC | 33.01M | $543.36M | $387.07M | -$156.29M | -28.76% |
 Christina Forster Pazienza Guardian Partners Inc. | 595,998 | $1.81M | $6.25M | $4.45M | 246.2% |
AbCellera Biologics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RW Robert Wasserman Benchmark | 2,124.88 | $16,340.34 | $22,253.88 | $5,913.54 | 36.19% |
AbCellera Biologics Inc. (ABCL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AbCellera Biologics Inc. ever had a stock split?
AbCellera Biologics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Carl Hansen CEO | NASDAQ (NGS) Exchange | 00288U106 CUSIP |
| CA Country | 562 Employees | - Last Dividend | - Last Split | 11 Dec 2020 IPO Date |
Overview
AbCellera Biologics Inc. is a pioneering entity in the biotechnology sector, focusing on revolutionizing the approach towards antibody drug discovery and development. The company leverages a unique engine that harnesses the power of natural immune responses to discover antibodies. This innovative platform is not only capable of identifying these vital antibodies but also pre-enriches them, streamlining the path from discovery to development. Since its inception in 2012, AbCellera has established itself as a key player in the biotech industry, forming strategic alliances with prominent companies like Eli Lilly, Confo Therapeutics, and Biogen Inc. These collaborations aim to accelerate the discovery of therapeutic antibody candidates across various medical conditions, including metabolic and endocrine disorders, atopic dermatitis, and neurological conditions. Headquartered in Vancouver, Canada, AbCellera continues to push the boundaries of medical science, charting new territories in antibody discovery and drug development.
Products and Services
AbCellera Biologics Inc. offers a range of preclinical products and services aimed at tackling some of the most challenging conditions in the medical field today. The company's expertise in antibody discovery and development has enabled the inception of several promising preclinical candidates, along with strategic partnerships focused on advancing therapeutic solutions.
- ABCL635 - This preclinical product is designed to address metabolic and endocrine conditions. Leveraging AbCellera's antibody discovery engine, ABCL635 represents a significant step forward in the treatment of diseases that affect millions of people worldwide.
- ABCL575 - Focused on atopic dermatitis, ABCL575 emerges from the company's platform as another testament to its innovative approach towards treating complex skin conditions. This product embodies AbCellera's commitment to providing relief to those afflicted by atopic dermatitis.
In addition to these preclinical products, AbCellera's strategic collaborations underline its role as a versatile partner in the drug discovery process:
- Eli Lilly and Company: A research collaboration and license agreement focused on the development of antibody-based therapies. This partnership highlights AbCellera's capability in bringing its discovery engine to bear on large-scale pharmaceutical development projects.
- Confo Therapeutics: This research collaboration is aimed at discovering therapeutic antibody candidates targeting two undisclosed GPCR targets. It showcases AbCellera's adaptability in exploring new therapeutic areas and potential targets.
- Biogen Inc.: A strategic collaboration with Biogen underscores AbCellera's expansion into neurological conditions, leveraging its antibody discovery and development expertise to tackle some of the most pressing challenges in neurology.
